What Arzeda does

Arzeda is a Seattle-based protein design company founded in 2009 as a spinout from David Baker's lab at the University of Washington Institute for Protein Design. The company builds proprietary software (Archytas™ for enzyme design, Scylax™ for metabolic pathway design) on top of an Intelligent Protein Design Technology™ platform that combines physics-based protein design with generative AI trained on 15+ years of proprietary structured design-and-assay data. An agentic AI layer orchestrates closed-loop Design-Build-Test-Learn cycles across strain engineering, bioprocess, and formulation workflows, claimed to deliver 10–100x higher hit rates versus conventional screening.

Arzeda generates revenue through three principal mechanisms: (i) commercial product sales of AI-designed ingredients, led by ViaLeaf™ Reb M — a high-purity (95%) steviol glycoside sweetener produced via cell-free biomanufacturing at 500+ MT/year capacity across two continents — and the ProSweet Enzymes™ portfolio; (ii) multi-year co-development partnerships with milestone-based funding and commercialization value-share agreements with Fortune 500 enterprises including Unilever, W.L. Gore & Associates, Takeda, AAK, BP, Amyris, MANE, and KENT Specialty Milling; and (iii) non-dilutive grant funding from NSF (~$14.1M across CFIRE and USPRD cell-free biomanufacturing consortiums in 2025) and DARPA. Pricing for ViaLeaf is positioned at roughly two-thirds the replacement cost of sugar and requires 48% less sweetener usage than incumbent Reb A at 8% sugar equivalent, with Non-GMO Project Verified status achieved October 2025.

The company's go-to-market is enterprise field sales targeting Fortune 500 CPG and specialty chemical manufacturers, layered with strategic channel partnerships (notably MANE for sweeteners and Unilever for home care), event-driven customer development (IFT FIRST, SynBioBeta, Natural Products Expo West), and direct website/email engagement for partnership inquiries. Arzeda has raised over $83M in disclosed equity funding across a $12M Series A (2017), $33M Series B (2022), and $38M oversubscribed round (2024), and is led by co-founder/CEO Alexandre Zanghellini alongside a recently expanded C-suite (COO Alex Patist, CTO Paula Hicks, both appointed June 2026) and a board chaired by Bill Baum.

Name

Arzeda

Legal name

Arzeda Corporation

Website

https://arzeda.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

51–100 employees

Short description

Arzeda is a Seattle-based generative AI protein design company that designs, validates, and manufactures novel proteins and enzymes for Fortune 500 partners in food, home care, materials, and pharmaceuticals.

Ownership category

akta.pro rank

Product category

Synthetic Biology / Protein Design & Biomanufacturing

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), Therapeutic Enzymes & Enzyme Replacement Therapies (ERT) (HLAAAAAK), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)

Keywords

• Computational protein design
• AI enzyme engineering
• Synthetic biology platform
• Protein biomanufacturing
• Novel enzyme development

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Designer Protein and Enzyme Licensing/Product Sales: Arzeda designs, manufactures, and sells proprietary designer proteins and enzymes to customers. Primary commercial product is ViaLeaf™ Reb M (stevia sweetener) sold to food and beverage companies. Also sells ProSweet Enzymes™ portfolio to sweetener companies. Revenue from product sales of manufactured proteins.
2. Co-development and Milestone Payments: Strategic partnerships with Fortune 500 companies involve milestone-based funding for development programs. Partners like Amyris provide milestone-based payments plus commercialization value-share. BP collaboration includes funding for enzyme design toward renewable chemical production. DARPA award provides funding for AI-driven protein design for national security applications.
3. Technology Platform Commercialization: Platform technology licensed to partners for specific applications. Collaboration with W.L. Gore for materials, AAK for plant-based oils, Unilever for home care enzymes, Takeda for pharma biologics. Partners gain access to Arzeda's protein design capabilities while Arzeda retains technology ownership.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

Arzeda designs, validates, and manufactures novel proteins and enzymes using a generative AI platform (Intelligent Protein Design Technology™) that combines physics-based protein design, proprietary AI/ML models trained on 15+ years of structured data, and an agentic closed-loop Design-Build-Test-Learn system. The company sells these designer proteins and enzymes as commercial products (notably ViaLeaf™ Reb M stevia sweetener and ProSweet Enzymes™) and engages in co-development partnerships with Fortune 500 companies across food/nutrition, home care, materials, and pharmaceutical sectors. Arzeda also licenses its protein design capabilities and proprietary software platforms (Archytas™, Scylax™) to industrial partners.

Differentiator

Problem solved

Functional benefit

Brands

• ViaLeaf™ Reb M: High-purity steviol glycoside sweetener produced through AI-designed enzymes via cell-free biomanufacturing. Achieves 95% purity with cleaner sweetness profile and less bitterness than Reb A.
• ProSweet Enzymes™
• ProSweet Reb M™
• Intelligent Protein Design Technology™
• Archytas™
• SENSE CAPTURE™

Products and services

• ViaLeaf™ Reb M ViaLeaf™ Reb M is a high-purity (95%) steviol glycoside natural sweetener ingredient produced via AI-designed enzymes and cell-free biomanufacturing from stevia leaf extract. It offers cleaner sweetness profile with significantly less bitterness than Reb A, requires 48% less sweetener at 8% SEV, and is sold to food and beverage companies as a clean-label, Non-GMO Project Verified sugar reduction ingredient at commercial scale (>500 metric tons/year).
• ProSweet Enzymes™ ProSweet Enzymes™ is a portfolio of AI-designed enzymes sold to sweetener manufacturers and ingredient producers for efficient, scalable production of high-purity Reb D and Reb M steviol glycosides from stevia leaf extract. The enzymes deliver consistent purity and are used by commercial stevia ingredient producers.
• AI-Designed Home Care Enzymes A designer-enzyme product line for home and personal care formulations including cleaning and laundry products. Developed through a multi-year strategic partnership with Unilever, the enzymes deliver improved stability, performance, and sustainability benefits and could halve the number of ingredients needed for effective cleaning, supporting Unilever's Clean Future and net-zero emissions by 2039 commitments.
• Protein-Enhanced Advanced Materials Protein-enhanced materials developed through Arzeda's Intelligent Protein Design Technology™ under a joint development agreement with W.L. Gore & Associates. Targets novel categories of durability, functionality, and feel for advanced materials applications while reducing environmental footprint compared to traditional synthetic chemistry.
• Computational Protein Biologics Design (Takeda Collaboration) Computational protein design services applying AI-driven protein optimization to therapeutic proteins (antibodies, enzyme replacement therapies, biologics) for pharmaceutical partners including Takeda. Uses physics-based design and machine learning to accelerate biologics development.

Quantifiable outcome

• 5× faster enzyme development: Unilever enzymes developed in 18 months vs. traditional timeline
• +8 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature9 records

Partnerships

14 partnerships are on record, tiered core.

• KENT Specialty MillingcoreStrategic or Co-development Partner · 5 May 2026Product development agreement announced May 5, 2026 combining Arzeda's Intelligent Protein Design Technology™ with KENT's manufacturing scale and market expertise. Collaboration aims to develop novel proteins with tailored performance characteristics for customer-focused solutions. KENT is a division of KENT WORLDWIDE (headquartered in Muscatine, Iowa, founded 1927) known for animal care, human nutrition, and specialty ingredients.
• MANEcoreStrategic or Co-development Partner · 5 March 2026Strategic partnership announced March 5, 2026 to commercialize ViaLeaf™ Reb M. MANE brings global production capabilities, commercial reach, and expertise in flavor creation and taste modulation. Integrates MANE's SENSE CAPTURE™ technologies. Collaboration focuses on reduced-sugar beverages and broader food/beverage reformulation. Partnership addresses clean-label, natural sugar reduction challenges driven by sugar taxes and regulatory pressure.
• Missouri University of Science and TechnologycoreStrategic or Co-development Partner · 30 September 2025Academic partner in NSF CFIRE consortium ($7.8M) for electricity-driven cell-free biomanufacturing. Collaboration includes development of electricity-powered enzyme cascades for sustainable chemical production.
• Novonesis A/ScoreStrategic or Co-development Partner · 30 September 2025Industry partner in NSF CFIRE consortium. Novonesis is a global leader in industrial enzyme manufacturing. Partnership advances cell-free bioelectrodes for industrial adoption with focus on CO2-to-methanol conversion.
• Stanford UniversitycoreStrategic or Co-development Partner · 8 September 2025Academic partner in NSF USPRD consortium (~$6.3M) for scaling industrial cell-free biomanufacturing. Multi-disciplinary team integrates AI-driven protein design, high-throughput testing, and advanced bioprocess engineering.
• University of North Carolina at Chapel HillcoreStrategic or Co-development Partner · 8 September 2025Academic partner in NSF USPRD consortium for cell-free manufacturing through AI-designed enzymes operating on cost-effective non-natural cofactors.
• University of California, IrvinecoreStrategic or Co-development Partner · 8 September 2025Academic partner in NSF USPRD consortium advancing cell-free biomanufacturing technology toward widespread industrial adoption.
• University of California, DaviscoreStrategic or Co-development Partner · 8 September 2025Academic partner in NSF USPRD consortium contributing to cell-free manufacturing research and development.
• TakedacoreStrategic or Co-development Partner · 21 March 2023Collaboration announced March 2023 to apply Arzeda's Intelligent Protein Design Technology™ to optimize therapeutic proteins in Takeda's biologics research pipeline. Uses computational design and machine learning to accelerate optimization of proteins for therapeutic products. Addresses design challenges historically slowing biologics development.
• AAKcoreStrategic or Co-development Partner · 18 October 2022Joint development agreement to create sustainable plant-based oils for the food industry. Leverages Arzeda's protein design platform to enhance sustainability profile and production efficiency of AAK's specialty oils and fats. AAK is a global leader in specialty oils and fats with extensive experience in enzyme technology application.
• W. L. Gore & AssociatescoreStrategic or Co-development Partner · 27 June 2022Initial collaboration in June 2022 expanded to joint development agreement in September 2023. Gore's venture arm invested in Arzeda's September 2024 funding round. Collaboration aims to develop next-generation protein-enhanced materials with superior performance and reduced environmental footprint. Gore cited 'next generation materials with superior performance with a reduced environmental footprint' as investment rationale.
• UnilevercoreStrategic or Co-development Partner · 13 July 2021Multi-year strategic partnership since July 2021 to design new generation of enzymes for Unilever's cleaning and laundry products. Supports Unilever's Clean Future strategy to remove virgin fossil-fuel feedstocks. Partnership developed enzymes 5x faster than previous methods (18 months). Enzymes will halve ingredients needed while delivering superior cleaning. Unilever commitment: net-zero emissions from all products by 2039.
• AmyriscoreStrategic or Co-development Partner · 20 October 2020Second joint project between companies. Arzeda designs novel enzymes for Amyris fermentation processes producing high-value ingredients. Milestone-based funding with additional payment contingent on early success plus value-share on commercialization. Previous collaboration on DARPA TIA (2015-2019). Enzymes designed are not found in nature, demonstrating computational platform capability.
• BPcoreStrategic or Co-development Partner · 2 October 2018Joint development agreement for producing renewable chemical with broad applications. Phase 1 successfully completed; expanded to second phase in December 2019 accelerating toward commercialization. Arzeda uses Archytas™ software and high-throughput protein construction/testing to design enzymes enabling BP's proprietary pathways. BP brings world-class expertise and capital for sustainable chemical commercialization.

Scale indicators15 records

Recent moves8 records

Expansion highlights6 records

Emerging players

• Isomorphic Labs: Isomorphic Labs is Alphabet's AI-first drug discovery company applying DeepMind's protein structure prediction to therapeutic design. It represents a well-capitalized emerging competitor in AI-enabled biologic discovery platforms, though focused on pharma rather than industrial enzymes.
• Cradle: Cradle is an emerging AI protein design platform focused on accelerating protein engineering for biotech and industrial applications. It uses generative AI similar to Arzeda's approach but with different methods and a focus on platform licensing rather than integrated product commercialization.

Broad incumbents

• Novonesis: Novonesis (formerly Novozymes) is the global leader in industrial enzyme manufacturing, partnering with Arzeda in the NSF CFIRE consortium. It is a broad incumbent with massive scale in food, home care, and industrial enzyme markets that Arzeda's designed enzymes compete against or complement.
• DSM-firmenich: DSM-firmenich is a global leader in nutrition, health, and beauty ingredients including enzymes and stevia sweeteners. It is a broad incumbent that competes with Arzeda's ViaLeaf Reb M in the natural sweetener market and has massive distribution scale.
• Ginkgo Bioworks: Ginkgo Bioworks is a synthetic biology platform company that designs and programs organisms for industrial applications across food, pharma, and materials. It acquired Zymergen's HZN automation platform, making it a broad incumbent comparable to Arzeda in platform-based bioengineering, though with different technology approaches and broader scope.

Others

• TeselaGen: TeselaGen provides cloud-based DNA design and synthetic biology automation tools. It is an enabling technology partner to Arzeda (licensing agreement) and adjacent ecosystem player in the computational bioengineering space.

Direct peers

• Geltor: Geltor produces animal-free proteins for beauty and food applications using precision fermentation. Its former COO (now Arzeda COO Alex Patist) provides direct leadership overlap, and the company uses synthetic biology to produce designer proteins at scale like Arzeda.
• Bolt Threads: Bolt Threads is a synthetic biology company producing engineered proteins and sustainable materials for fashion and beauty. Its former SVP (now Arzeda COO Alex Patist) brings direct operational experience, and the companies share the protein-based biomanufacturing model.
• Codexis: Codexis is a protein engineering company that develops engineered enzymes for pharmaceutical, food, and industrial applications. Codexis is a co-investor in Arzeda through the SynBio Innovation Accelerator and is directly comparable in commercial enzyme engineering across similar verticals.
• Amyris: Amyris is a synthetic biology company that engineered yeast strains to produce ingredients for cosmetics, flavors, and fragrances. Arzeda has had multiple development partnerships with Amyris dating to 2015, making them a direct peer in fermentation-based ingredient production.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/arzeda-corp
• Xx.com/ArzedaCo
• Facebookfacebook.com/157862827577345

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds17 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arzeda